Logo image of SAVA

CASSAVA SCIENCES INC (SAVA) Stock Overview

NASDAQ:SAVA - US14817C1071 - Common Stock

2.2 USD
+0.05 (+2.33%)
Last: 8/22/2025, 8:00:02 PM
2.22 USD
+0.02 (+0.91%)
After Hours: 8/22/2025, 8:00:02 PM

SAVA Key Statistics, Chart & Performance

Key Statistics
52 Week High33.98
52 Week Low1.15
Market Cap106.28M
Shares48.31M
Float42.13M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.5
PEN/A
Fwd PE21.57
Earnings (Next)11-05 2025-11-05
IPO07-14 2000-07-14
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


SAVA short term performance overview.The bars show the price performance of SAVA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10

SAVA long term performance overview.The bars show the price performance of SAVA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of SAVA is 2.2 USD. In the past month the price decreased by -6.38%. In the past year, price decreased by -92.89%.

CASSAVA SCIENCES INC / SAVA Daily stock chart

SAVA Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 44.07 673.58B
JNJ JOHNSON & JOHNSON 17.93 431.79B
NVO NOVO-NORDISK A/S-SPONS ADR 14.69 253.19B
AZN ASTRAZENECA PLC-SPONS ADR 18.24 251.05B
NVS NOVARTIS AG-SPONSORED ADR 14.35 245.81B
MRK MERCK & CO. INC. 11.35 218.23B
PFE PFIZER INC 7.63 147.14B
SNY SANOFI-ADR 11.64 125.24B
BMY BRISTOL-MYERS SQUIBB CO 7.12 97.54B
GSK GSK PLC-SPON ADR 8.95 81.01B
ZTS ZOETIS INC 25.18 69.41B
TAK TAKEDA PHARMACEUTIC-SP ADR 53.52 49.02B

About SAVA

Company Profile

SAVA logo image Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 30 full-time employees. The company went IPO on 2000-07-14. The firm's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. The company has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.

Company Info

CASSAVA SCIENCES INC

6801 N. Capital of Texas Highway, Building 1

Austin TEXAS 78731 US

CEO: Remi Barbier

Employees: 30

SAVA Company Website

SAVA Investor Relations

Phone: 15125012444

CASSAVA SCIENCES INC / SAVA FAQ

What is the stock price of CASSAVA SCIENCES INC today?

The current stock price of SAVA is 2.2 USD. The price increased by 2.33% in the last trading session.


What is the ticker symbol for CASSAVA SCIENCES INC stock?

The exchange symbol of CASSAVA SCIENCES INC is SAVA and it is listed on the Nasdaq exchange.


On which exchange is SAVA stock listed?

SAVA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CASSAVA SCIENCES INC stock?

6 analysts have analysed SAVA and the average price target is 2.04 USD. This implies a price decrease of -7.27% is expected in the next year compared to the current price of 2.2. Check the CASSAVA SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CASSAVA SCIENCES INC worth?

CASSAVA SCIENCES INC (SAVA) has a market capitalization of 106.28M USD. This makes SAVA a Micro Cap stock.


How many employees does CASSAVA SCIENCES INC have?

CASSAVA SCIENCES INC (SAVA) currently has 30 employees.


What are the support and resistance levels for CASSAVA SCIENCES INC (SAVA) stock?

CASSAVA SCIENCES INC (SAVA) has a support level at 2.16 and a resistance level at 2.3. Check the full technical report for a detailed analysis of SAVA support and resistance levels.


Should I buy CASSAVA SCIENCES INC (SAVA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CASSAVA SCIENCES INC (SAVA) stock pay dividends?

SAVA does not pay a dividend.


When does CASSAVA SCIENCES INC (SAVA) report earnings?

CASSAVA SCIENCES INC (SAVA) will report earnings on 2025-11-05.


What is the Price/Earnings (PE) ratio of CASSAVA SCIENCES INC (SAVA)?

CASSAVA SCIENCES INC (SAVA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.5).


What is the Short Interest ratio of CASSAVA SCIENCES INC (SAVA) stock?

The outstanding short interest for CASSAVA SCIENCES INC (SAVA) is 15.01% of its float. Check the ownership tab for more information on the SAVA short interest.


SAVA Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to SAVA. When comparing the yearly performance of all stocks, SAVA is a bad performer in the overall market: 96.34% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SAVA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to SAVA. No worries on liquidiy or solvency for SAVA as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SAVA Financial Highlights

Over the last trailing twelve months SAVA reported a non-GAAP Earnings per Share(EPS) of -1.5. The EPS increased by 30.88% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -51.65%
ROE -57.04%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-11.63%
Sales Q2Q%N/A
EPS 1Y (TTM)30.88%
Revenue 1Y (TTM)N/A

SAVA Forecast & Estimates

6 analysts have analysed SAVA and the average price target is 2.04 USD. This implies a price decrease of -7.27% is expected in the next year compared to the current price of 2.2.


Analysts
Analysts43.33
Price Target2.04 (-7.27%)
EPS Next Y61.31%
Revenue Next YearN/A

SAVA Ownership

Ownership
Inst Owners32.46%
Ins Owners5.73%
Short Float %15.01%
Short Ratio6.61